For Intramuscular Use Only
NOT FOR USE IN PEDIATRIC PATIENTS
Trimethobenzamide hydrochloride is a sterile solution for intramuscular injection. Each 1 mL contains 100 mg trimethobenzamide hydrochloride compounded with 0.45% phenol as preservative, 0.5 mg sodium citrate anhydrous and 0.2 mg citric acid anhydrous as buffers, and 0.1 mg edetate disodium as stabilizer in Water for Injection. pH is adjusted with sodium hydroxide or hydrochloric acid.
Trimethobenzamide hydrochloride injection is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Media Articles Related to Trimethobenzamide
Netupitant/palonosetron for prevention of nausea and vomiting: Added benefit not proven
Source: Cancer / Oncology News From Medical News Today [2015.11.24]
Certain advantages in side effects, but equivalence of main effect has not been proven.
Nausea and Vomiting
Source: MedicineNet Angina Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM
Published Studies Related to Trimethobenzamide
Randomized, placebo-controlled trial of trimethobenzamide to control nausea and
vomiting during initiation and continued treatment with subcutaneous apomorphine
may not be needed, although this has not been systematically studied... CONCLUSION: Our data suggest that trimethobenzamide helps reduce nausea/vomiting
A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. [2006.06]
BACKGROUND: Although various classes of medication are used to treat acute migraine in the emergency department (ED), no treatment offers complete pain relief without side effects or recurrence of headache. Consequently, even though several antiemetic medications as well as SQ sumatriptan have demonstrated efficacy and tolerability for the ED treatment of migraine, there remains a need for more effective parenteral therapies. Open-label studies suggest that the combination of trimethobenzamide and diphenhydramine (TMB/DPH) may provide effective relief in a high proportion of migraineurs. OBJECTIVE: To test the hypothesis that ED patients with acute migraine, given intramuscular TMB/DPH, would have a larger reduction in their pain scores than patients given SQ sumatriptan... CONCLUSIONS: SQ sumatriptan is probably superior to TMB/DPH for treating the pain of acute migraine at 2 hours. However, TMB/DPH was well-tolerated, efficacious, and relieved pain comparably to sumatriptan at 24 hours. TMB/DPH might have a role in select populations in which sumatriptan is contraindicated or likely to be ineffective.
Clinical Trials Related to Trimethobenzamide
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects [Completed]
This study will test the hypothesis that PF-06649751 with continuous co-administration of
trimethobenzamide hydrochloride (TMB) with will be safe and well tolerated. Single doses of
PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose
projected to be under the current limits for drug concentration.
Safety/Efficacy of Tigan´┐Ż to Control Nausea/Vomiting Experienced During Apokyn´┐Ż Initiation and Treatment [Completed]
The purposes of the study are to determine:
i. To assess the efficacy of Tigan« (trimethobenzamide) in preventing nausea and vomiting
when initiating therapy with Apokyn« (apomorphine)
ii. To determine the optimal duration for continuation of Tigan« following initiation of
iii. To assess the safety of Tigan┬« in combination with Apokyn┬«
iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated
concomitantly with and without Tigan┬«
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Completed]
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease [Recruiting]
This is a study with two sequential cohorts, each with three treatment periods. Single doses
of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose
projected to be under the current limits for drug concentration. Each cohort will aim to
achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary
endpoint is MDS-UPDRS part III.
Corneal Staining Associated With Daily Disposable Beauty Contact Lenses [Terminated]
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Trimethobenzamide has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Trimethobenzamide review by 41 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Vertigo|
|Dosage & duration:|| || 300mg taken 1x 8 hours for the period of 4-5 days|
|Other conditions:|| || None|
|Other drugs taken:|| || Meclizine|
|Benefits:|| || The trimethobenzamide significantly reduced nausea and brought it down to a perceptible but comfortable level.|
|Side effects:|| || None.|
|Comments:|| || After being diagnosed with temporary vertigo, I was given prescriptions for this plus Meclizine for dizziness. The two combined brought the vertigo completely under control. There were no side effects. I took the medication as originally prescribed for two days and then, at my doctor's suggestion, reduced the amount to as-needed. The trimethobenzamide made it possible to eat normally, with no uncomfortable feelings of nausea.|
Page last updated: 2015-11-24